Case-Based Roundtable Meetings Spotlight: February 1, 2022

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed the results of several major trials of drug combinations in patients with renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Madappa Kundranda, MD, PhD, and participants discussed the case of a patient with recently diagnosed, unresectable colorectal cancer.

During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.

During a Targeted Oncology case-based roundtable event, Matthew A. Lunning, DO, discussed the results of the L-MIND study of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Shirish M Gadgeel, MD, discussed the results of the ALEX, ALTA-1L, and CROWN studies of immune checkpoint inhibitors in non–squamous non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Francis Paul Worden, MD, discussed treatment options for a patient with high-risk basal cell carcinoma.